Midatech Pharma (MTP) seeking strategic alternatives

POTENTIAL DEAL DETAILS

Midatech Pharma PLC (MTP), an R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients announces that, in view of prevailing conditions in the capital markets and the prospects for raising additional funds and partnering of assets, the Board of Midatech is in the process of implementing a strategic review of its operations.

Update(s):

April 20, 2020: Midatech Pharma PLC (MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines announces an update to the previously announced strategic review and the appointment of Noble as an adviser.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.